C-peptide microheterogeneity in type 2 diabetes populations

Paul E. Oran, Jason W. Jarvis, Chad Borges, Randall W. Nelson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to investigate naturally occurring C-peptide micro-heterogeneity in healthy and type 2 diabetes (T2D) populations. Experimental design: MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D. Results: Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D. Conclusions and clinical relevance: C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.

Original languageEnglish (US)
Pages (from-to)106-111
Number of pages6
JournalProteomics - Clinical Applications
Volume4
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

C-Peptide
Medical problems
Type 2 Diabetes Mellitus
Population
Dipeptidyl Peptidase 4
Human Body
Immunoassay
Design of experiments
Research Design
Plasmas

Keywords

  • C-peptide
  • Microheterogeneity
  • Population proteomics
  • Variants

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

C-peptide microheterogeneity in type 2 diabetes populations. / Oran, Paul E.; Jarvis, Jason W.; Borges, Chad; Nelson, Randall W.

In: Proteomics - Clinical Applications, Vol. 4, No. 1, 01.2010, p. 106-111.

Research output: Contribution to journalArticle

Oran, Paul E. ; Jarvis, Jason W. ; Borges, Chad ; Nelson, Randall W. / C-peptide microheterogeneity in type 2 diabetes populations. In: Proteomics - Clinical Applications. 2010 ; Vol. 4, No. 1. pp. 106-111.
@article{c1594b635bd945699f64da3843ec3ca9,
title = "C-peptide microheterogeneity in type 2 diabetes populations",
abstract = "Purpose: The purpose of this study was to investigate naturally occurring C-peptide micro-heterogeneity in healthy and type 2 diabetes (T2D) populations. Experimental design: MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D. Results: Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D. Conclusions and clinical relevance: C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.",
keywords = "C-peptide, Microheterogeneity, Population proteomics, Variants",
author = "Oran, {Paul E.} and Jarvis, {Jason W.} and Chad Borges and Nelson, {Randall W.}",
year = "2010",
month = "1",
doi = "10.1002/prca.200800249",
language = "English (US)",
volume = "4",
pages = "106--111",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - C-peptide microheterogeneity in type 2 diabetes populations

AU - Oran, Paul E.

AU - Jarvis, Jason W.

AU - Borges, Chad

AU - Nelson, Randall W.

PY - 2010/1

Y1 - 2010/1

N2 - Purpose: The purpose of this study was to investigate naturally occurring C-peptide micro-heterogeneity in healthy and type 2 diabetes (T2D) populations. Experimental design: MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D. Results: Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D. Conclusions and clinical relevance: C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.

AB - Purpose: The purpose of this study was to investigate naturally occurring C-peptide micro-heterogeneity in healthy and type 2 diabetes (T2D) populations. Experimental design: MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D. Results: Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D. Conclusions and clinical relevance: C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.

KW - C-peptide

KW - Microheterogeneity

KW - Population proteomics

KW - Variants

UR - http://www.scopus.com/inward/record.url?scp=77951758248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951758248&partnerID=8YFLogxK

U2 - 10.1002/prca.200800249

DO - 10.1002/prca.200800249

M3 - Article

C2 - 21137020

AN - SCOPUS:77951758248

VL - 4

SP - 106

EP - 111

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 1

ER -